Integral Diagnostics (ASX:IDX) ROCE %: 4.79% (As of Dec. 2025)


ASX:IDX Integral Diagnostics Ltd ASX:IDX
73 GF Score
Price A$2.01
GF Value A$2.78
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Integral Diagnostics ROCE %?

Integral Diagnostics ASX:IDX +1.77% 73 ROCE % is 4.79% as of Dec. 2025. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Integral Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.79%.

Integral Diagnostics  (ASX:IDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Integral Diagnostics ROCE % Related Terms

Integral Diagnostics ROCE % Historical Data

* Premium members only.

The historical data trend for Integral Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integral Diagnostics ROCE % Chart

Integral Diagnostics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.95 5.16 6.72 -5.67 3.21

Integral Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.35 4.31 2.58 3.04 4.79
ASX:IDX
73GF Score
Integral Diagnostics Ltd ASX:IDX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integral Diagnostics ROCE % Calculation

Integral Diagnostics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=31.165/( ( (744.276 - 85.683) + (1426.47 - 140.66) )/ 2 )
=31.165/( (658.593+1285.81)/ 2 )
=31.165/972.2015
=3.21 %

Integral Diagnostics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=61.642/( ( (1426.47 - 140.66) + (1423.724 - 133.435) )/ 2 )
=61.642/( ( 1285.81 + 1290.289 )/ 2 )
=61.642/1288.0495
=4.79 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.79% mean?
Integral Diagnostics (ASX:IDX) has a ROCE % of 4.79% as of Dec. 2025.
Is Integral Diagnostics' ROCE % too high?
Integral Diagnostics' current ROCE % is 4.79%. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' ROCE % compare to TMO and DHR?
Integral Diagnostics' ROCE % of 4.79% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Integral Diagnostics's current ROCE % is 4.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.01 — trading 27.7% below its estimated fair value. The current ROCE % is 4.79%. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current ROCE % is 4.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?

Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued. The current stock price of A$2.01 is trading 27.7% below its estimated GF Value™ of A$2.78. GuruFocus considers Integral Diagnostics to be Modestly Undervalued.

Key valuation signals for ASX:IDX:

  • ROCE %: 4.79%
  • GF Value™: A$2.78 vs. price of A$2.01 (27.7% below fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integral Diagnostics Business Description

Address 288 Victoria Parade, Level 2, Melbourne, VIC, AUS, 3002
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score

Get the complete analysis for ASX:IDX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.01
Price
A$2.78
GF Value